Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin on Lorlatinib PK in Healthy Volunteers
NCT02804399Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2016
- Primary completion
- Oct 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Plasma Area Under the Curve from Time Zero to Infinity at Day 8 and Maximum Plasma Concentration at Day 8. Started Jul 2016; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02804399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02804399.